First Page | Document Content | |
---|---|---|
Date: 2017-03-27 02:02:40 | # 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim WiAdd to Reading ListSource URL: www.biolinerx.comDownload Document from Source WebsiteFile Size: 915,67 KBShare Document on Facebook |